Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth
Galectin-8 (Gal-8), a ‘tandem-repeat’-type galectin, has been described as a modulator of cellular functions including adhesion, spreading, growth arrest, apoptosis, pathogen recognition, autophagy, and immunomodulation. We have previously shown that activated leukocyte cell adhesion molecule (ALCAM...
Guardado en:
Autores principales: | , , , , , , , , , |
---|---|
Formato: | JOUR |
Materias: | |
Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_01674889_v_n_p_Ferragut |
Aporte de: |
id |
todo:paper_01674889_v_n_p_Ferragut |
---|---|
record_format |
dspace |
spelling |
todo:paper_01674889_v_n_p_Ferragut2023-10-03T15:04:53Z Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth Ferragut, F. Cagnoni, A.J. Colombo, L.L. Sánchez Terrero, C. Wolfenstein-Todel, C. Troncoso, M.F. Vanzulli, S.I. Rabinovich, G.A. Mariño, K.V. Elola, M.T. ALCAM (CD166) Cell adhesion and migration Galectin-8 N-glycosylation Sialylation Triple negative breast cancer Tumor growth Galectin-8 (Gal-8), a ‘tandem-repeat’-type galectin, has been described as a modulator of cellular functions including adhesion, spreading, growth arrest, apoptosis, pathogen recognition, autophagy, and immunomodulation. We have previously shown that activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, serves as a receptor for endogenous Gal-8. ALCAM is a member of the immunoglobulin superfamily involved in cell-cell adhesion through homophilic (ALCAM-ALCAM) and heterophilic (i.e. ALCAM-CD6) interactions in different tissues. Here we investigated the physiologic relevance of ALCAM-Gal-8 association and glycosylation-dependent mechanisms governing these interactions. We found that silencing of ALCAM in MDA-MB-231 triple negative breast cancer cells decreases cell adhesion and migration onto Gal-8-coated surfaces in a glycan-dependent fashion. Remarkably, either Gal-8 or ALCAM silencing also disrupted cell-cell adhesion, and led to reduced tumor growth in a murine model of triple negative breast cancer. Moreover, structural characterization of endogenous ALCAM N-glycosylation showed abundant permissive structures for Gal-8 binding. Importantly, we also found that cell sialylation controls Gal-8-mediated cell adhesion. Altogether, these findings demonstrate a central role of either ALCAM or Gal-8 (or both) in controlling triple negative breast cancer. © 2019 Elsevier B.V. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_01674889_v_n_p_Ferragut |
institution |
Universidad de Buenos Aires |
institution_str |
I-28 |
repository_str |
R-134 |
collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
topic |
ALCAM (CD166) Cell adhesion and migration Galectin-8 N-glycosylation Sialylation Triple negative breast cancer Tumor growth |
spellingShingle |
ALCAM (CD166) Cell adhesion and migration Galectin-8 N-glycosylation Sialylation Triple negative breast cancer Tumor growth Ferragut, F. Cagnoni, A.J. Colombo, L.L. Sánchez Terrero, C. Wolfenstein-Todel, C. Troncoso, M.F. Vanzulli, S.I. Rabinovich, G.A. Mariño, K.V. Elola, M.T. Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth |
topic_facet |
ALCAM (CD166) Cell adhesion and migration Galectin-8 N-glycosylation Sialylation Triple negative breast cancer Tumor growth |
description |
Galectin-8 (Gal-8), a ‘tandem-repeat’-type galectin, has been described as a modulator of cellular functions including adhesion, spreading, growth arrest, apoptosis, pathogen recognition, autophagy, and immunomodulation. We have previously shown that activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, serves as a receptor for endogenous Gal-8. ALCAM is a member of the immunoglobulin superfamily involved in cell-cell adhesion through homophilic (ALCAM-ALCAM) and heterophilic (i.e. ALCAM-CD6) interactions in different tissues. Here we investigated the physiologic relevance of ALCAM-Gal-8 association and glycosylation-dependent mechanisms governing these interactions. We found that silencing of ALCAM in MDA-MB-231 triple negative breast cancer cells decreases cell adhesion and migration onto Gal-8-coated surfaces in a glycan-dependent fashion. Remarkably, either Gal-8 or ALCAM silencing also disrupted cell-cell adhesion, and led to reduced tumor growth in a murine model of triple negative breast cancer. Moreover, structural characterization of endogenous ALCAM N-glycosylation showed abundant permissive structures for Gal-8 binding. Importantly, we also found that cell sialylation controls Gal-8-mediated cell adhesion. Altogether, these findings demonstrate a central role of either ALCAM or Gal-8 (or both) in controlling triple negative breast cancer. © 2019 Elsevier B.V. |
format |
JOUR |
author |
Ferragut, F. Cagnoni, A.J. Colombo, L.L. Sánchez Terrero, C. Wolfenstein-Todel, C. Troncoso, M.F. Vanzulli, S.I. Rabinovich, G.A. Mariño, K.V. Elola, M.T. |
author_facet |
Ferragut, F. Cagnoni, A.J. Colombo, L.L. Sánchez Terrero, C. Wolfenstein-Todel, C. Troncoso, M.F. Vanzulli, S.I. Rabinovich, G.A. Mariño, K.V. Elola, M.T. |
author_sort |
Ferragut, F. |
title |
Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth |
title_short |
Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth |
title_full |
Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth |
title_fullStr |
Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth |
title_full_unstemmed |
Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth |
title_sort |
dual knockdown of galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (alcam/cd166), synergistically delays in vivo breast cancer growth |
url |
http://hdl.handle.net/20.500.12110/paper_01674889_v_n_p_Ferragut |
work_keys_str_mv |
AT ferragutf dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth AT cagnoniaj dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth AT colomboll dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth AT sanchezterreroc dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth AT wolfensteintodelc dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth AT troncosomf dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth AT vanzullisi dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth AT rabinovichga dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth AT marinokv dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth AT elolamt dualknockdownofgalectin8anditsglycosylatedligandtheactivatedleukocytecelladhesionmoleculealcamcd166synergisticallydelaysinvivobreastcancergrowth |
_version_ |
1782027620514267136 |